Whether this would have direct implications to inactive MS lesions is uncertain but a recent study by Stephen Strittmatter’s group at Yale School of Medicine successfully demonstrated that glial scar formation was significantly reduced in a chronic non-human primate model of SCI utilizing the daily delivery of the NgR1(310)-Fc (AXER-204) (Wang et al., 2020), currently an active clinical phase I trial in chronic SCI (ClinicalTrials.gov, NCT03989440). The gene discussed is RTN4R; the disease is myeloid sarcoma.